Institutional members access full text with Ovid®

Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda

Srikantiah, Padminia,b; Walusimbi, Maria Nc; Kayanja, H Kosed; Mayanja-Kizza, Harrietc; Mugerwa, Roy Dc; Lin, Roycea; Charlebois, Edwin Db; Boom, W Henryd; Whalen, Christopher Cd; Havlir, Diane Va

doi: 10.1097/QAD.0b013e32823ecf6e
Research Letters

Triple nucleoside reverse transcriptase inhibitors are recommended as an alternative regimen for HIV-infected patients undergoing tuberculosis treatment in resource-limited settings. Few data exist on the efficacy of such regimens in tuberculosis patients. In 34 tuberculosis/HIV-co-infected patients treated with zidovudine/lamivudine/abacavir, 76% achieved HIV RNA less than 50 copies/ml at 24 weeks. No cases of hypersensitivity or immune reconstitution syndrome were observed. These data support the continuing evaluation of nucleoside-based antiretroviral regimens as an alternative treatment for this population.

aHIV/AIDS Division, San Francisco General Hospital, University of California, San Francisco, California, USA

bCenter for AIDS Prevention Studies, University of California, San Francisco, California, USA

cMakerere University School of Medicine, Mulago Hospital, Uganda–CWRU Research Collaboration, Kampala, Uganda

dTuberculosis Research Unit, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Received 30 March, 2007

Accepted 10 April, 2007

© 2007 Lippincott Williams & Wilkins, Inc.